[go: up one dir, main page]

RU95103741A - Medicinal agent for acid-alkaline equilibrium and an aqueous-electrolyte balance disorder normalization - Google Patents

Medicinal agent for acid-alkaline equilibrium and an aqueous-electrolyte balance disorder normalization

Info

Publication number
RU95103741A
RU95103741A RU95103741/14A RU95103741A RU95103741A RU 95103741 A RU95103741 A RU 95103741A RU 95103741/14 A RU95103741/14 A RU 95103741/14A RU 95103741 A RU95103741 A RU 95103741A RU 95103741 A RU95103741 A RU 95103741A
Authority
RU
Russia
Prior art keywords
aqueous
chloride
electrolyte balance
children
normalization
Prior art date
Application number
RU95103741/14A
Other languages
Russian (ru)
Other versions
RU2056837C1 (en
Inventor
В.П. Мерзлов
В.В. Алексеев
А.С. Новохатский
В.С. Кондратьев
Н.Д. Ломоносова
Г.Н. Хлябич
Original Assignee
Государственный институт кровезаменителей и медицинских препаратов
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Государственный институт кровезаменителей и медицинских препаратов filed Critical Государственный институт кровезаменителей и медицинских препаратов
Priority to RU95103741A priority Critical patent/RU2056837C1/en
Application granted granted Critical
Publication of RU2056837C1 publication Critical patent/RU2056837C1/en
Publication of RU95103741A publication Critical patent/RU95103741A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

FIELD: medicine, pharmacy. SUBSTANCE: proposed preparation is used for correction of an aqueous-electrolyte balance and metabolic acidosis in adult and children as a component of infusion therapy. Preparation is used by intravenous route. Daily dose for adult is 5-20 mg/kg, for children - 5-10 mg/kg for 3-5 days. Preparation consists of an aqueous solution of the following salts: sodium chloride, potassium chloride, calcium chloride, magnesium chloride and sodium acetate. EFFECT: enhanced effectiveness of agent.

Claims (1)

Изобретение относится к медицине и медицинской промышленности (растворы лекарственные). Квинтасоль - препарат для коррекции водно-электролитного баланса и метаболического ацидоза - применяют у взрослых и детей как компонент инфузионной терапии. Квинтасоль применяют внутривенно. Суточная доза для взрослых 5 - 20 мг/кг, для детей - 5 - 10 мг/кг. Курс лечения составляет 3 - 5 дней. Препарат представляет собой водный раствор солей: хлорида натрия, хлорида калия, хлорида кальция, хлорида магния и ацетата натрия.The invention relates to medicine and the medical industry (medicinal solutions). Quintasol, a drug for the correction of water-electrolyte balance and metabolic acidosis, is used in adults and children as a component of infusion therapy. Quintasol is administered intravenously. The daily dose for adults is 5 to 20 mg / kg, for children is 5 to 10 mg / kg. The course of treatment is 3 to 5 days. The drug is an aqueous solution of salts: sodium chloride, potassium chloride, calcium chloride, magnesium chloride and sodium acetate.
RU95103741A 1995-03-22 1995-03-22 Medicinal agent for normalization of acid-alkaline equilibrium and aqueous-electrolyte balance disturbance RU2056837C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU95103741A RU2056837C1 (en) 1995-03-22 1995-03-22 Medicinal agent for normalization of acid-alkaline equilibrium and aqueous-electrolyte balance disturbance

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU95103741A RU2056837C1 (en) 1995-03-22 1995-03-22 Medicinal agent for normalization of acid-alkaline equilibrium and aqueous-electrolyte balance disturbance

Publications (2)

Publication Number Publication Date
RU2056837C1 RU2056837C1 (en) 1996-03-27
RU95103741A true RU95103741A (en) 1997-02-27

Family

ID=20165661

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95103741A RU2056837C1 (en) 1995-03-22 1995-03-22 Medicinal agent for normalization of acid-alkaline equilibrium and aqueous-electrolyte balance disturbance

Country Status (1)

Country Link
RU (1) RU2056837C1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1068778C (en) * 1998-05-15 2001-07-25 赵超英 Novel drug composition for treating and curing and its preparing method
RU2185173C2 (en) * 2000-09-20 2002-07-20 Государственный институт кровезаменителей и медицинских препаратов Preparation of hemodynamic action with the function for normalization of acid-base balance and electrolyte one
RU2224504C1 (en) * 2002-08-09 2004-02-27 Нестерук Владимир Викторович Method of preparing solution "khlosol"
RU2342101C1 (en) * 2007-10-02 2008-12-27 Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук Maintenance and correction method of water-electrolytic balance in primates
RU2342100C1 (en) * 2007-10-02 2008-12-27 Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук Maintenance and correction method of water-electrolytic balance in mammals
RU2423987C1 (en) * 2009-12-31 2011-07-20 Государственное образовательное учреждение высшего профессионального образования САНКТ-ПЕТЕРБУРГСКАЯ ГОСУДАРСТВЕННАЯ ХИМИКО-ФАРМАЦЕВТИЧЕСКАЯ АКАДЕМИЯ Федерального агентства по здравоохранению и социальному развитию (ГОУ ВПО СПХФА Росздрава) Infusion solution for total blood volume replacement, hydro-electrolytic rebalancing and hematopoiesis process normalisation

Also Published As

Publication number Publication date
RU2056837C1 (en) 1996-03-27

Similar Documents

Publication Publication Date Title
US4870061A (en) Use of N-acetylglucosamine for the therapy of degenerative joint disease and related diseases
AU2011324137B2 (en) A combination composition
ES2117642T3 (en) PHARMACEUTICAL PREPARATION CONTAINING N-GLYCOFUROLES AND N-ETILEN GLYCOLS.
GB2100985A (en) Compositions containing buprenorphine
KR970025615A (en) Cancer metastasis inhibitor
US5015481A (en) Stabilized pharmaceutical admixture composition
RU95103741A (en) Medicinal agent for acid-alkaline equilibrium and an aqueous-electrolyte balance disorder normalization
US11090315B1 (en) Prevention and treatment of flu-type viral infections and related complications
JPS6333332A (en) Agent for suppressing growth of aids virus
US3873709A (en) Method of treating psychosis
RU2138255C1 (en) Method of treatment of patients with diseases of viral etiology
JP2004315470A (en) Pharmaceutical preparation containing sodium iodide
RU2113805C1 (en) Food additive "yantavit"
US4990513A (en) Antihypoxic drug and method of its application
US5955498A (en) Agent for prophylaxis and therapy of diseases
EP0256629A2 (en) Tolrestat or a salt thereof as an immuno-stimulating agent
RU2077330C1 (en) Method of meningococcal infection treatment
RU2131733C1 (en) Method of attenuation and prophylaxis of abstinent syndrome and agent for its realizing
US3423508A (en) Method of combatting herpes virus with 5-nitrouracil
WO2019171162A1 (en) Parenteral acetaminophen for intravenous administration fortified with amino acids and vitamin for counteracting acetaminophen induced hepatotoxicity and nephrotoxicity
RU2002104753A (en) Method for the prevention and treatment of cattle leukemia
US4731380A (en) Tolerstat as an agent for diabetic periodontitis
US3806594A (en) Method of reducing involuntary movements associated with cerebral palsy using clorazepate dipotassium
JP2000229853A (en) Menstrual pain improving composition
SU301951A1 (en) MEDICINE

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner